Nuevo dispositivo para la detecci\u00f3n precoz del c\u00e1ncer de mama.<\/p>\n
Madrid. 1st October 2024<\/strong>. The Fundaci\u00f3n Te\u00f3filo Hernando (FTH) is pleased to announce its participation in an international, prospective, multicentric clinical study of a medical device for the early detection of breast cancer. The participation of two sites in Spain, the Hospital Universitario de Toledo and the Hospital Universitario Reina Sof\u00eda de C\u00f3rdoba, have already been launched and patient recruitment has already begun. The University Hospital of Toledo has already participated in the previous validation phase of the device, with Dr Cristina Romero as principal investigator and clinical coordinator.<\/p>\n The clinical investigation is framed within the international research project MammoScreen, co-funded by the European Commission and UK Research and Innovation under the Horizon Europe The overall aim of the MammoScreen project is to generate evidence on the use of MammoWave (a new device which avoids ionising radiations and breast compression), as breast cancer screening technique in population-based cohort already included in programs promoted by national or regional health systems. The goal is to make screening more accurate, inclusive and comfortable for women.<\/p>\n MammoWave uses very low-power, totally safe radio frequencies to generate microwaves images of the breasts and proved to be effective also in dense breast. Women lie face down, in a comfortable position, while the test is performed in less than ten minutes per breast.<\/p>\n This initiative is of great scientific and social importance, given that breast cancer is the most diagnosed among European women, with up to 190 new cases and 45 deaths per 100000 women.<\/p>\n","protected":false},"excerpt":{"rendered":" Nuevo dispositivo para la detecci\u00f3n precoz del c\u00e1ncer de mama. The Te\u00f3filo Hernando Foundation (FTH), CRO in Spain and Portugal, supports a clinical study with a new device for the early detection of breast cancer The participation of two of the participating sites in Spain, Hospital Universitario de Toledo and Hospital Universitario Reina Sof\u00eda de […]<\/p>\n","protected":false},"author":3,"featured_media":3915,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-3777","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-estudio"],"yoast_head":"\n
\nprogramme (Grant Agreement: 101097079), and is coordinated by Fondazione Toscana Life Sciences – TLS ( Italy). The study promoter is Umbria Bioengineering Technologies-UBT (Italy), in collaboration with JSB Solutions SRL, and will have the FTH as the CRO in charge of data monitoring and follow-up for Spain and Portugal. . In addition to the University Hospital of Toledo (which is also a partner in the MammoScreen project) and the Reina Sofia University Hospital in Cordoba, another site in Spain, the Morales Meseguer University Hospital in Murcia, will soon begin its participation. In Portugal, two sites have been participating since March 2024, the Champalimaud Foundation and the Dr. Angelo Passos Clinic. The study is also being conducted in Italy, Poland and Switzerland, and has already recruited 500 women in the active sites.<\/p>\n